Navigation Links
Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
Date:12/5/2008

WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH) from December 6-9, 2008 in San Francisco, California.

Clinical investigators from leading oncology and hematology research centers will present data through several oral and poster presentations reporting important findings in leukemia-related disorders, such as prognostic indicators for chronic lymphocytic leukemia (CLL) and side effects such as chemotherapy-induced neutropenia.

Campath is indicated in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Leukine is indicated for use following induction chemotherapy in patients 55 years and older with acute myelogenous leukemia (AML) to shorten the time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.

"We are pleased to see continued developments on both Campath and Leukine," said Pam Cyrus, Vice President, Medical Affairs, Oncology, Bayer HealthCare Pharmaceuticals. "These studies further demonstrate Bayer's ongoing commitment to supporting research to benefit the lives of people living with cancer."

Abstracts are now available on the ASH Web site at http://www.hematology.org.

Among the data that will be presented are the following:

Campath:

  • Poster 3164 (December 8, 5:30 p.m. PST) -- Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study Within Various Cytogenetic Risk Categories

  • Poster 329 (December 8, 12:00 p.m
    '/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
2. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
3. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
6. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
7. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
8. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
9. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
10. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
11. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , FRAZER, Pa., Dec. 2 /PRNewswire-Fi...announced that it has filed a lawsuit in U.S. Dist...s USA, Inc. for infringement of U.S. Patent Nos. 7... Patent") and RE37,516 (the ",516 Patent") for the...ets [C-IV]. Cephalon has a three-year period of m...
(Date:12/2/2009)..., , NEW YORK, Dec. 2 ...rch report is available in its catalogue: ,, H..., http://www.reportlinker.com/p0164230/Hemoglo..., The seriousness of affliction and the need for...he emergence of a significant market for monitorin...
(Date:12/2/2009)..., , NEW YORK, Dec. 2 ...rch report is available in its catalogue: ,, H...e of Market Trends & Opportunities ,, htt...s-And-Therapeutics---A-Global-Update-of-Market-Tre...itnessed for all these years of meager clinical ou...
Breaking Medicine Technology:Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 2Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 3Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 4Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 5Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 6Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 7Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 8Ecological Society of America announces 2009 award recipients 9060 1Ecological Society of America announces 2009 award recipients 9060 2Ecological Society of America announces 2009 award recipients 9060 3Oscar Pistorius 3A Previously confidential study results released on amputee sprinter 9056 1Oscar Pistorius 3A Previously confidential study results released on amputee sprinter 9056 2Perot Systems Wins Over 24119 Million CDC Contract 50319 1Perot Systems Wins Over 24119 Million CDC Contract 50319 2
(Date:12/2/2009)...sity could counter recent increases in longevity ,... The overall health of the U.S. population has imp... people have quit smoking in droves, but a new stu... the rising obesity rates among Americans don,t le...oking and obesity continue unchanged, the average ...
(Date:12/2/2009)...etabolic syndrome, study finds , , WEDNE...n,t enough to keep overweight college football pla...tion that can lead to heart disease, a new study s...ion I colleges and found that two-thirds were obes...group of conditions that raise the risk for heart ...
(Date:12/2/2009)...y more to come, NIH director says, , , ...em cell lines have been added to the pool that sci...many more such lines will soon be made available, ...ese are the first additional embryonic stem cell l...onal Institutes of Health (NIH) since President Ba...
(Date:12/2/2009)...ec. 2 By now, most people have hea...continue to grow in popularity. And, the latest pr...mEcigarette - the new single piece PremiumOne(TM) ... low price of $14.99. ,, "This new product make... a very low price, before making a bigger investme...
(Date:12/2/2009)...c. 2 Researchers from a...od cancer research at the annual American Society ...mber 4-8, 2009. ,, Throughout the ASH conferen...rts, including Chief Medical Officer Barton Kamen,...vices Hildy Dillon, and Vice President, Research C...
Breaking Medicine News(10 mins):Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:Oversized College Football Players May Face Heart Risks 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2
...e 20 Bob Hamilton was named Vice,President of Ham...comes to,Hamilton Medical with a financial backgro... utilized by such companies as Smith Barney,Citigr...forward to great things for the future., (Phot...
... -- The Damon Runyon Cancer Research Foundation na...ts May 2008 Clinical Investigator Award Committee ...-year award are outstanding early career physician...ns. Each will receive $450,000 to support the dev...
...- The American College of Physicians (ACP) today c...(MedPAC) for its recognition of the importance of ...ivery system in its June 2008 Report to Congress. ...ss on issues affecting the Medicare program. ,In a...
...ents should think carefully about test that has no...une 20 (HealthDay News) -- While CT screening may ...ormer smokers, it won,t reduce the risk of death f... from 1,520 current and former smokers who took pa...
...C., June 20 Blockbusters are not,discovered, they...start,early, listen carefully, and spend wisely. T...ma product launches, top performers have developed...unching a Blockbuster: The Making,and Marketing of...
... US $50 Million over a Five-Year Period to Improve...ARCH TRIANGLE PARK, N.C., June 20 The,U.S. Agency...ed that Family,Health International (FHI) -- a glo...ning Services)., The project will generate knowle...
Other Medicine News:Health News:Damon Runyon Cancer Research Foundation awards $2.25M to 5 top young clinical investigators 2Health News:Damon Runyon Cancer Research Foundation awards $2.25M to 5 top young clinical investigators 3Health News:American College of Physicians commends MedPAC June 2008 report to Congress 2Health News:American College of Physicians commends MedPAC June 2008 report to Congress 3Health News:CT Screens for Lung Cancer Not a Cure-All 2Health News:Family Health International Awarded USAID 'Progress' Project to Improve Family Planning and Reproductive Health Programs in Developing Countries 2Health News:Family Health International Awarded USAID 'Progress' Project to Improve Family Planning and Reproductive Health Programs in Developing Countries 3
Vest Guard (Vest for Men)
EZ Guard, Adjustable Fit Apron
Economy Tie - Lead Apron
Qualcraft™ Lead-Free Back-Aid Radiation Protection Apron
Medicine Products: